Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexamethylbenzene SCHEMBL5430986 | 1.00 | HCRTR2 (0.33) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL5413840 | 0.92 | HTT (0.33) | LMNA | |
| SCHEMBL5424758 | 0.92 | HTT (0.33) | LMNA | |
| SCHEMBL5180239 | 0.90 | CA1 (0.37) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL810240 | 0.90 | CA1 (0.37) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL5180894 | 0.90 | CA1 (0.37) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL5180231 | 0.90 | CA1 (0.37) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL5180906 | 0.90 | CA1 (0.37) | HCRTR2MMP2MMP9CA12CA1 | |
| SCHEMBL5424477 | 0.90 | LMNA (0.37) | PTGS1PTGS2LMNAHDAC4 | |
| SCHEMBL5429405 | 0.90 | LMNA (0.37) | PTGS1PTGS2LMNAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20040176616-A1 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176616-A1 | Process for producing optically active compound | OSTC, NPEPPS, PPOX | HCRTR2 4802/4885MMP2 3386/4885MMP9 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.